Comparative efficacy of the Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV vaccines against infection with circulating feline Calicivirus.

Abstract

BACKGROUND: Feline calicivirus (FCV) is a common virus, found worldwide, mainly responsible for chronic ulceroproliferative faucitis and periodontitis. This virus has a high mutation rate, leading to the presence of numerous FCV strains in the field. The objectives of this study was to evaluate and compare the efficacy of two vaccines (Leucofeligen&#x2122; FeLV/RCP and Purevax&#x2122; RCP FeLV), which differ by their nature (live vs. inactivated) and the vaccinal strains, against circulating FCV strains. Thirty 9-week-old specific pathogen free (SPF) kittens were thus randomised into 3 groups and were either not vaccinated (control) or vaccinated (2 injections, 3&#xa0;weeks apart) with one of the vaccines. Four weeks after the second injection of primary vaccination, the cats were inoculated with a pathogenic strain representative of the ones circulating in Europe (FCV-FR4_01) and followed for 2&#xa0;weeks. RESULTS: After challenge, significant differences (p&#xa0;<&#xa0;0.05) between control cats and cats vaccinated with Leucofeligen&#x2122; FeLV/RCP or Purevax&#x2122; RCP FeLV were observed for body weight variation, rectal temperature rise and maximum clinical scores, reflecting the intensity of the signs (83% and 67% lower in the respective vaccinated groups than in the control group). Significant differences were observed between the vaccinated groups, as cats vaccinated with Leucofeligen&#x2122; FeLV/RCP had a lower temperature rise (p&#xa0;<&#xa0;0.05 at days post-challenge 3 to 5) and lower virus shedding titres (p&#xa0;<&#xa0;0.05 at days post-challenge 8, 9 and 11) than cats vaccinated with Purevax&#x2122; RCP FeLV. Finally, only cats vaccinated with Leucofeligen&#x2122; FeLV/RCP had a significantly lower cumulative score, reflecting the intensity and duration of calicivirosis clinical signs, than the control cats (77% lower vs. 62% lower for cats vaccinated with Purevax&#x2122; RCP FeLV). CONCLUSIONS: Both vaccines, Leucofeligen&#x2122; FeLV/RCP and Purevax&#x2122; RCP FeLV, were found to be efficacious in reducing clinical signs induced by FCV-FR4_01, a FCV strain representative of the circulating ones. However, cats vaccinated with Leucofeligen&#x2122; FeLV/RCP were able to control the infection more efficiently than those vaccinated with Purevax&#x2122; RCP FeLV, as evidenced by the shorter duration of clinical signs and lower viral titre in excretions.